Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia

医学 肺癌 化疗 肿瘤科 内科学 PD-L1 免疫检查点 癌症研究 癌症 免疫疗法
作者
Yuki Kato,Hibiki Udagawa,Shingo Matsumoto,Hiroki Izumi,Y. Ohe,Terufumi Kato,Kazumi Nishino,Shingo Miyamoto,Sachiko Kawana,Kenichi Chikamori,Masato Shingyoji,Yutaka Satō,Yuji Takada,Ryo Toyozawa,Koichi Azuma,Yu Tanaka,Tetsuya Sakai,Yuji Shibata,Eri Sugiyama,Kaname Nosaki,Yoshitaka Zenke,Shigeki Umemura,Kiyotaka Yoh,Masahiro Seike,Kōichi Goto
出处
期刊:Lung Cancer [Elsevier]
卷期号:197: 107992-107992
标识
DOI:10.1016/j.lungcan.2024.107992
摘要

Highlights•ICIs plus chemotherapy prolonged the PFS in HER2-mutant NSCLC.•TMB was higher in the tumors harboring HER2 mutations compared to EGFR mutations.•The relatively high TMB might be involved in the prolongation of the PFS.AbstractIntroductionHER2 mutations are reported to occur in 2%–5% of all cases of non-small cell lung cancer (NSCLC). The clinical outcomes in patients with HER2-mutant NSCLC treated with immune checkpoint inhibitors (ICIs) plus platinum-based chemotherapy as 1st line treatment still remain unclear.MethodsUsing the large-scale clinico-genomic database of LC-SCRUM-Asia, the clinico-genomic characteristics and therapeutic outcomes of patients with HER2-mutant NSCLC were investigated.ResultsOf the 15,251 patients with NSCLC enrolled in the LC-SCRUM-Asia database, tumor HER2 mutations were detected in 402 patients (2.6 %). The most common subtype of HER2 mutations was exon 20 in-frame insertions (79 %), followed in frequency by mutations in the tyrosine kinase domain other than Exon20ins (10 %) and mutations in extracellular domains (7 %). NSCLCs harboring HER2 mutations showed a higher tumor mutation burden (TMB) as compared with NSCLCs harboring EGFR mutations or ALK fusions (median: 4.22 vs. 2.54 and 2.52 mutation per megabase, respectively). Of the 402 patients, 268 patients had received platinum-based chemotherapy with ICIs (Chemo-ICI, n = 95) or without ICI (Chemo-alone, n = 173) as 1st line treatment. The progression-free survival (PFS) was significantly longer in the Chemo-ICI group as compared with the Chemo-alone group (median 8.5 vs. 6.3 months; HR [95 %CI]: 0.66 [0.50–0.88]; P < 0.005). Multivariate analysis identified use of ICIs in addition to platinum-based chemotherapy as an independent favorable prognostic factor for PFS. There was no significant difference in the overall survival between the patients of the Chemo-ICI and Chemo-alone groups (median 31.1 vs. 23.3 months; HR [95 %CI]: 0.80 [0.57–1.12], P = 0.20).ConclusionsAddition of ICIs to platinum-based chemotherapy in 1st line treatment may improve the PFS in patients with HER2-mutant NSCLC. The relatively high TMB might be involved in the prolongation of the PFS in patients with HER2-mutant NSCLC receiving platinum-based chemotherapy with ICIs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宇文青寒发布了新的文献求助10
刚刚
coconut发布了新的文献求助10
1秒前
1秒前
Joo完成签到,获得积分10
2秒前
2秒前
orixero应助上进生采纳,获得10
3秒前
3秒前
4秒前
4秒前
5秒前
医路有你发布了新的文献求助10
6秒前
努力的小狗屁应助陈一采纳,获得30
7秒前
7秒前
7秒前
高高的丹雪完成签到 ,获得积分10
7秒前
jx314完成签到,获得积分10
8秒前
yumemakase发布了新的文献求助10
8秒前
抗体小王完成签到,获得积分10
8秒前
8秒前
9秒前
迪er发布了新的文献求助10
9秒前
丘比特应助玛卡巴卡采纳,获得10
9秒前
lapidary完成签到,获得积分20
10秒前
高高的丹雪关注了科研通微信公众号
10秒前
10秒前
10秒前
pengxixi50694完成签到,获得积分10
11秒前
和平星发布了新的文献求助10
12秒前
orixero应助金桂琴采纳,获得10
14秒前
端庄书雁完成签到,获得积分10
15秒前
1364135702发布了新的文献求助10
15秒前
美满的天薇完成签到,获得积分20
15秒前
皮戾完成签到 ,获得积分10
15秒前
瘦瘦问旋完成签到,获得积分10
16秒前
爆米花应助丰富芷荷采纳,获得10
16秒前
FashionBoy应助慢慢采纳,获得10
16秒前
王权富贵完成签到,获得积分20
16秒前
幽悠梦儿完成签到 ,获得积分10
17秒前
小二郎应助阿曼采纳,获得10
17秒前
wei完成签到,获得积分10
17秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3156221
求助须知:如何正确求助?哪些是违规求助? 2807720
关于积分的说明 7874164
捐赠科研通 2465918
什么是DOI,文献DOI怎么找? 1312504
科研通“疑难数据库(出版商)”最低求助积分说明 630154
版权声明 601912